Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases
Annovis Bio, Inc. (ANVS)
Company Research
Source: GlobeNewswire
BERWYN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, was issued a patent (US 10,383,851) in August 2019 for a method of treating Parkinson’s disease, Lewy body dementia and other Lewy body diseases in humans by administering its lead compound, ANVS401. The Company expects multiple patents to be generated from this patent family, each targeting specific neurodegenerative diseases independently. Maria Maccecchini, Ph.D., CEO of Annovis, commented, “Based on discussions with the patent office, we have filed additional patent applications for each individual neurodegenerative disease that our drug targets. We plan to provide further updates as we execute on this process.” ANVS401 improves axonal transport, the information highway of the nerve cell, by attacking multiple neurotoxic proteins simultaneously. ANVS401 is the lead compound in th
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace [Yahoo! Finance]Yahoo! Finance
- Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s MarketplaceGlobeNewswire
- /C O R R E C T I O N -- Today's Marketplace/PR Newswire
- Annovis to Host Year-End Investor Webcast on December 11, 2024 [Yahoo! Finance]Yahoo! Finance
- Annovis to Host Year-End Investor Webcast on December 11, 2024GlobeNewswire
ANVS
Earnings
- 11/11/24 - Beat
ANVS
Sec Filings
- 12/11/24 - Form 8-K
- 12/11/24 - Form 8-K
- 12/11/24 - Form 424B5
- ANVS's page on the SEC website